1. Home
  2. Cbd Products

Cbd Products

Bod broadens UK sales footprint as CBD skincare market grows

Finfeed Archived Jun 17, 2021

Following the launch of two new CBD-based products under the CBII brand, Bod Australia Limited (ASX: BDA) today announced that it has broadened its sales footprint in the United Kingdom via two new online retailers.

CPH set to expand in $300M Latin American CBD market

Finfeed Archived Jun 04, 2021

The expansion of its comprehensive distribution agreement with leading nutritional supplements company Route2 Pharm Pvt Ltd, will allow for distribution of Creso Pharma Limited's (ASX: CPH, FRA: 1X8) hemp derived therapeutic products sold under the cannaQIX® and CannaDOL brands into Ecuador.

Revenue generating BDA sets its sights on US market

Finfeed Archived Mar 17, 2021

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

Creso Pharma’s CBD for pets secures regulatory approval in Latin America

Finfeed Archived Dec 21, 2020

Creso Pharma Limited (ASX: CPH, FRA: 1X8) has secured regulatory approval from the Ministry of Agriculture and Animal Feed in Uruguay (Ministerio de Ganadaria, Agricultura y Pesca) through its commercial partner Adler Laboratories, Uruguay for its line of animal health products, anibidiol®.

How Creso Pharma could benefit from TGA down-scheduling of CBD

Finfeed Archived Dec 15, 2020

Creso Pharma (ASX: CPH) is positioned to significantly benefit from a TGA decision to down-schedule low dose CBD preparations.

Positive regulatory ramifications for CPH from US Marijuana Act

Finfeed Archived Dec 07, 2020

Creso Pharma Limited (ASX: CPH; FRA: 1X8) has advised that the US House of Representatives has passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act to remove cannabis for the US Controlled Substances Act.

Creso Pharma poised to cash in on CBD regulatory changes

Finfeed Archived Nov 30, 2020

Creso Pharma (ASX: CPH) has provided a promising update regarding the regulatory status of cannabidiol (CBD) products in Europe.

Changes to OTC cannabis sales just around the corner

Finfeed Archived Nov 26, 2020

The Therapeutic Goods Administration (TGA) will shortly bring down its final decision regarding a major regulatory change in the distribution of cannabidiol (CBD) products in Australia, which could hellp stocks such as Creso Pharma (ASX: CPH).

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X